Здравоохранение Кыргызстана
Zdravoohraneniye Kyrgyzstana

ISSN 1694-8068 (Print)

ISSN 1694-805X (Online)

Войти

Является ли благоприятным назначение метформина у пациентов с хронической сердечной недостаточностью ишемической этиологии на этапе инсулинорезистентности?

https://doi.org/10.51350/zdravkg202231320
Является ли благоприятным назначение метформина у пациентов с хронической сердечной недостаточностью ишемической этиологии на этапе инсулинорезистентности?
Полный текст Full text Толук текст  

PDF (RUS)

PDF (RUS)

PDF (RUS)
Аннотация Об авторах Список литературы

Аннотация

Хроническая сердечная недостаточность (ХСН) и сахарный диабет (СД) 2 типа часто сосуществуют. ХСН в настоящее время рассматривается как состояние инсулинорезистентности (ИР) и ассоциируется с ухудшением прогноза и качества жизни пациентов. Благоприятное влияние метформина на течение сердечно-сосудистых заболеваний, ХСН в частности, у пациентов с СД 2 типа, установлено в ходе многочисленных исследований. Целью настоящего исследования является оценка влияния метформина на клиническое течение ХСН ишемической этиологии у пациентов на этапе ИР. Материал и методы. В ходе открытого, проспективного рандомизированого клинического исследования 76 пациентов с ХСН ишемической этиологии (средний возраст 62 (57,5-65) лет, мужчин (n=44), средняя фракция выброса левого желудочка (ФВ ЛЖ) 44,0% (34-52,5)), были рандомизированы на 2 группы: с приемом метформина (n=39) и без приема (n=37), соответственно. Всем пациентам выданы и подробно разъяснены принципы модификации образа жизни. ИР диагностирована при HOMA-IR ≥ 2.5. Не- обходимые объективные (с опросом о качестве жизни пациентов с ХСН), лабораторные и инструментальные методы исследования, 6-минутный тест с ходьбой были провены исходно и через 12 месяцев наблюдения. Результаты. Терапия метформином ассоциировалась с улучшением таких ХСН-ассоциированных клинических индикаторов, как: ИР (HOMA-IR), показатели альдостерона, функциональная способность и качество жизни. Также в группе с метформином отмечалось достоверное улучшение почечной функции (по показателям креатинина и суточной протеинурии) и средней ФВ ЛЖ. Заключение. Возможности благоприятного влияния метформина на течение ХСН ишемической этиологии у пациентов без сопутствующего СД 2 типа позволит оптимизировать стратегию вмешательств для улучшения качества жизни и долгосрочного прогноза при ХСН, а также снизить частоту конверсии в СД 2 типа.

Об авторах

Курманбекова Бермет Темирбековна, младший научный сотрудник отделения хронической сердечной недостаточности, Национальный центр кардиологии и терапии имени академика М.Миррахимова, Бишкек, Кыргызская Республика;
Норузбаева Айгуль Мукашевна, доктор медицинский наук, профессор, заведующая отделением хронической сердечной недостаточности, Национальный центр кардиологии и терапии имени академика М.Миррахимова, Бишкек, Кыргызская Республика;
Рустамбекова Акмарал Рустамбековна, младший научный сотрудник отделения хронической сердечной недостаточности, Национальный центр кардиологии и терапии имени академика М. Миррахимова, Бишкек, Кыргызская Республика.

Kurmanbekova Bermet Temirbekovna, young researcher at chronic heart failure division, National center of cardiology and internal medicine named after academician M.Mirrakhimov, Bishkek, Kyrgyz Republic;

Rustambekova Akmaral Rustambekovna, Junior Researcher, Department of Chronic Heart Failure, National Center for Cardiology and Therapy named after Academician M. Mirrakhimov,Bishkek, Kyrgyz Republic;
Noruzbaeva Aigul Mukashevna, MD, professor, the head of chronic heart failure division, National center of cardiology and internal medicine named after academician M.Mirrakhimov, Bishkek, Kyrgyz Republic.

Курманбекова Бермет Темирбековна, өнөкөт жүрөк жетишсиздиги бөлүмүнүн кенже илимий кызматкери, Академик М.Миррахимов атындагы улуттук кардиология жана терапия борбору, Бишкек, Кыргыз Республикасы;

Норузбаева Айгуль Мукашевна, медицина илимдеринин доктору, өнөкөт жүрөк жетишсиздиги бөлүмүнүн башчысы, Академик М.Миррахимов атындагы улуттук кардиология жана терапия борбору, Бишкек, Кыргыз Республикасы;

Рустамбекова Акмарал Рустамбековна, өнөкөт жүрөк жетишсиздиги бөлүмүнүн кенже илимий кызматкери, Академик М.Миррахимов атындагы улуттук кардиология жана терапия борбору, Бишкек, Кыргыз Республикасы.

Список литературы

1. Rosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev 2017; 3(1):52-55.doi:10.15420/cfr.2016:20:2
2. Joshua J.J, Justin B., Valery S.E et al. Renin-angiotensin-aldosterone system, glucose metabolism and incident of type 2 diabetes mellitus: MESA. https://doi.org/10.1161/JAHA.118.009890 Journal of the American Heart Association 2018;7:e009890
3. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 2012; 8(4):609-617. doi:10.1016/j.hfc.2012.06.005
4. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2):255–323.
5. Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic Effects of Metformin in the Failing Heart. Int J Mol Sci 2018;19(10):2869.
6. Wurm R, Resl M, Neuhold S, Prager R, Brath H, Francesconi C, et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Heart 2016; 102(19):1544–51.
7. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso, JS, Merkely B, et al. Risk related to pre–diabetes mellitus and diabetesmellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure 2016 Jan; 9(1):e002560.
8. Bilak JM, Gulsin GS, McCann GP. Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism January 2021. doi:10.1177/2042018820980235
9. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009 May 19; 119(19):2568-77.
10. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012 Apr 1; 61(4):944-53.
11. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. doi:10.3390/biom11121834
12. Larsen, A.H., Jessen, N., Nørrelund, H., Tolbod, L.P., Harms, H.J. et al (2020), A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail 22:1628-1637. https://doi.org/10.1002/ejhf.1656
13. Siyao He, Xin Qian, Yanyan Chen, Xiaoxia Shen et al "Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study", Journal of Diabetes Research vol. 2021, Article ID 5534387, 10 pages, 2021. https://doi.org/10.1155/2021/5534387
14. Han, Y., Xie, H., Liu, Y. et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery di seases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 18, 96 (2019). https://doi.org/10.1186/s12933-019-0900-7
15. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, et al The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 2012 Nov; 14(11):1303-10. doi: 10.1093/eurjhf/hfs106. Epub 2012 Jun 27. PMID: 22740509.
16. Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids 2014; 91:54-60. doi:10.1016/j.steroids.2014.08.016
17. Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr Metab Cardiovasc Dis 2017 Aug; 27(8):657-669. doi: 10.1016/j.numecd.2017.04.009. Epub 2017 May 10. PMID: 28709719.
18. Ohkuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017; 40(9):1203–9.
19. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119(1):70.e23-30.
20. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200–206
21. Top WMC, Lehert P, Schalkwijk CG, Stehouwer CDA, Kooy A. Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial. PLoS One 2021 Apr 8; 16(4):e0247939. doi:10.1371/journal.pone.0247939. PMID: 33830998; PMCID: PMC8031400.
22. Rosiak M, Postula M, Kaplon-Cieslicka A, Trzepla E et al Metformin treatment may be associated with decreased levels of NTproBNP in patients with type 2 diabetes. Adv Med Sci 2013; 58(2):362-8. doi: 10.2478/ams-2013-0009. PMID: 24327531.
23. Eltonsy S, Dufour Doiron M, Simard P, Jose C, Sénéchal M et al Effects of the combination of metformin and exercise on glycated hemoglobin, functional capacity, lipid profile, quality of life, and body weight. J Int Med Res 2019 Mar; 47(3):1131-1145. doi:10.1177/0300060518817164. Epub 2019 Jan 7. PMID: 30614342; PMCID: PMC6421378.
24. Banerjee S,Panas R. Diabetes and cardiorenal syndrome:Understanding the “Triple Threat”.Hellenic J Cardiol 2017; 58(5):342–7.

25. Ekundayo OJ, Muchimba M, Aban IB, Ritchie C, Campbell RC, Ahmed A. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am J Cardiol 2009; 103(1):88–92.
26. Kishi T, Hirooka Y. Cardiac complications in hypertension and diabetes: role of sympathetic nervous activity. Curr Hypertension Rev 2013; 9(4):274–7.
27. Damman K, Hillege HL, van Veldhuisen DJ. Albuminuria in heart failure: a CHARMing new risk factor? Lancet 2009;374(9689):506–8.
28. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006;17(8):2106–11
29. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22(4):584–603.
30. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med 2017; 166(3):191-200. doi:10.7326/M16-1901
31. Wiggers H, Køber L, Gislason G, Schou M, Poulsen MK, Vraa S, Nielsen OW, et al The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J 2021 Jan; 231:137-146. doi:10.1016/j.ahj.2020.09.020. Epub 2020 Oct 9. PMID: 33039340; PMCID: PM C7544566.
32. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. Doi: 10.3390/biom11121834.

1. Rosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev 2017; 3(1): 52-55. doi:10.15420/cfr.2016:20:2
2. Joshua J.J, Justin B., Valery S.E et al. Renin-angiotensin-aldosterone system, glucose metabolism and incident of type 2 diabetes mellitus: MESA. https://doi.org/10.1161/JAHA.118.009890 Journal of the American Heart Association 2018;7:e009890
3. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 2012; 8(4):609-617. doi:10.1016/j.hfc.2012.06.005
4. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2):255–323.
5. Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic Effects of Metformin in the Failing Heart. Int J Mol Sci  2018;19(10):2869.
6. Wurm R, Resl M, Neuhold S, Prager R, Brath H, Francesconi C, et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Heart 2016; 102(19):1544–51.
7. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso, JS, Merkely B, et al. Risk related to pre–diabetes mellitus and diabetesmellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure 2016 Jan; 9(1):e002560.
8. Bilak JM, Gulsin GS, McCann GP. Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism January 2021. doi:10.1177/2042018820980235
9. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009 May 19; 119(19):2568-77.
10. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012 Apr 1; 61(4):944-53.
11. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. doi:10.3390/biom11121834
12. Larsen, A.H., Jessen, N., Nørrelund, H., Tolbod, L.P., Harms, H.J. et al (2020), A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail 22:1628-1637. https://doi.org/10.1002/ejhf.1656
13. Siyao He, Xin Qian, Yanyan Chen, Xiaoxia Shen et al "Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study", Journal of Diabetes Research vol. 2021, Article ID 5534387, 10 pages, 2021. https://doi.org/10.1155/2021/5534387
14. Han, Y., Xie, H., Liu, Y. et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery di seases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 18, 96 (2019). https://doi.org/10.1186/s12933-019-0900-7
15. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, et al The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 2012 Nov; 14(11):1303-10. doi: 10.1093/eurjhf/hfs106. Epub 2012 Jun 27. PMID: 22740509.
16. Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids 2014; 91:54-60. doi:10.1016/j.steroids.2014.08.016
17. Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr Metab Cardiovasc Dis 2017 Aug; 27(8):657-669. doi: 10.1016/j.numecd.2017.04.009. Epub 2017 May 10. PMID: 28709719.
18. Ohkuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017; 40(9):1203–9.
19. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119(1):70.e23-30.
20. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200–206
21. Top WMC, Lehert P, Schalkwijk CG, Stehouwer CDA, Kooy A. Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial. PLoS One 2021 Apr 8; 16(4):e0247939. doi:10.1371/journal.pone.0247939. PMID: 33830998; PMCID: PMC8031400.
22. Rosiak M, Postula M, Kaplon-Cieslicka A, Trzepla E et al Metformin treatment may be associated with decreased levels of NTproBNP in patients with type 2 diabetes. Adv Med Sci 2013; 58(2):362-8. doi: 10.2478/ams-2013-0009. PMID: 24327531.
23. Eltonsy S, Dufour Doiron M, Simard P, Jose C, Sénéchal M et al Effects of the combination of metformin and exercise on glycated hemoglobin, functional capacity, lipid profile, quality of life, and body weight. J Int Med Res 2019 Mar; 47(3):1131-1145. doi:10.1177/0300060518817164. Epub 2019 Jan 7. PMID: 30614342; PMCID: PMC6421378.
24. Banerjee S,Panas R. Diabetes and cardiorenal syndrome:Understanding the “Triple Threat”.Hellenic J Cardiol 2017; 58(5):342–7.

25. Ekundayo OJ, Muchimba M, Aban IB, Ritchie C, Campbell RC, Ahmed A. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am J Cardiol 2009; 103(1):88–92.
26. Kishi T, Hirooka Y. Cardiac complications in hypertension and diabetes: role of sympathetic nervous activity. Curr Hypertension Rev 2013; 9(4):274–7.
27. Damman K, Hillege HL, van Veldhuisen DJ. Albuminuria in heart failure: a CHARMing new risk factor? Lancet 2009;374(9689):506–8.
28. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006;17(8):2106–11
29. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22(4):584–603.
30. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med 2017; 166(3):191-200. doi:10.7326/M16-1901
31. Wiggers H, Køber L, Gislason G, Schou M, Poulsen MK, Vraa S, Nielsen OW, et al The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J 2021 Jan; 231:137-146. doi:10.1016/j.ahj.2020.09.020. Epub 2020 Oct 9. PMID: 33039340; PMCID: PM C7544566.
32. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. Doi: 10.3390/biom11121834.

1. Rosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev 2017; 3(1): 52-55.doi:10.15420/cfr.2016:20:2
2. Joshua J.J, Justin B., Valery S.E et al. Renin-angiotensin-aldosterone system, glucose metabolism and incident of type 2 diabetes mellitus: MESA. https://doi.org/10.1161/JAHA.118.009890 Journal of the American Heart Association 2018;7:e009890
3. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 2012; 8(4):609-617. doi:10.1016/j.hfc.2012.06.005
4. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2):255–323.
5. Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic Effects of Metformin in the Failing Heart. Int J Mol Sci 2018;19(10):2869.
6. Wurm R, Resl M, Neuhold S, Prager R, Brath H, Francesconi C, et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Heart 2016; 102(19):1544–51.
7. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso, JS, Merkely B, et al. Risk related to pre–diabetes mellitus and diabetesmellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure 2016 Jan; 9(1):e002560.
8. Bilak JM, Gulsin GS, McCann GP. Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism January 2021. doi:10.1177/2042018820980235
9. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009 May 19; 119(19):2568-77.
10. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012 Apr 1; 61(4):944-53.
11. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. doi:10.3390/biom11121834
12. Larsen, A.H., Jessen, N., Nørrelund, H., Tolbod, L.P., Harms, H.J. et al (2020), A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail 22:1628-1637. https://doi.org/10.1002/ejhf.1656
13. Siyao He, Xin Qian, Yanyan Chen, Xiaoxia Shen et al "Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study", Journal of Diabetes Research vol. 2021, Article ID 5534387, 10 pages, 2021. https://doi.org/10.1155/2021/5534387
14. Han, Y., Xie, H., Liu, Y. et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery di seases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 18, 96 (2019). https://doi.org/10.1186/s12933-019-0900-7
15. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, et al The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 2012 Nov; 14(11):1303-10. doi: 10.1093/eurjhf/hfs106. Epub 2012 Jun 27. PMID: 22740509.
16. Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids 2014; 91:54-60. doi:10.1016/j.steroids.2014.08.016
17. Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr Metab Cardiovasc Dis 2017 Aug; 27(8):657-669. doi: 10.1016/j.numecd.2017.04.009. Epub 2017 May 10. PMID: 28709719.
18. Ohkuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017; 40(9):1203–9.
19. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119(1):70.e23-30.
20. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200–206
21. Top WMC, Lehert P, Schalkwijk CG, Stehouwer CDA, Kooy A. Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial. PLoS One 2021 Apr 8; 16(4):e0247939. doi:10.1371/journal.pone.0247939. PMID: 33830998; PMCID: PMC8031400.
22. Rosiak M, Postula M, Kaplon-Cieslicka A, Trzepla E et al Metformin treatment may be associated with decreased levels of NTproBNP in patients with type 2 diabetes. Adv Med Sci 2013; 58(2):362-8. doi: 10.2478/ams-2013-0009. PMID: 24327531.
23. Eltonsy S, Dufour Doiron M, Simard P, Jose C, Sénéchal M et al Effects of the combination of metformin and exercise on glycated hemoglobin, functional capacity, lipid profile, quality of life, and body weight. J Int Med Res 2019 Mar; 47(3):1131-1145. doi:10.1177/0300060518817164. Epub 2019 Jan 7. PMID: 30614342; PMCID: PMC6421378.
24. Banerjee S,Panas R. Diabetes and cardiorenal syndrome:Understanding the “Triple Threat”.Hellenic J Cardiol 2017; 58(5):342–7.

25. Ekundayo OJ, Muchimba M, Aban IB, Ritchie C, Campbell RC, Ahmed A. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am J Cardiol 2009; 103(1):88–92.
26. Kishi T, Hirooka Y. Cardiac complications in hypertension and diabetes: role of sympathetic nervous activity. Curr Hypertension Rev 2013; 9(4):274–7.
27. Damman K, Hillege HL, van Veldhuisen DJ. Albuminuria in heart failure: a CHARMing new risk factor? Lancet 2009;374(9689):506–8.
28. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006;17(8):2106–11
29. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22(4):584–603.
30. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med 2017; 166(3):191-200. doi:10.7326/M16-1901
31. Wiggers H, Køber L, Gislason G, Schou M, Poulsen MK, Vraa S, Nielsen OW, et al The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J 2021 Jan; 231:137-146. doi:10.1016/j.ahj.2020.09.020. Epub 2020 Oct 9. PMID: 33039340; PMCID: PM C7544566.
32. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. Doi: 10.3390/biom11121834.

Ключевые слова
хроническая сердечная недостаточность , инсулинорезистентность , метформин , клиническое течение
Для цитирования

Курманбекова Б.Т., Рустамбекова А.Р., Норузбаева А.М. Является ли благоприятным назначение метформина у пациентов с хронической сердечной недостаточностью ишемической этиологии на этапе инсулинорезистентности? Здравоохранение Кыргызстана 2022, № 1, с. 21-32.
https://doi.org/10.51350/zdravkg202231321
For citation

Kurmanbekova B.T., Rustambekova A.R., Noruzbaeva A.M. Is Metformin beneficial in ischemic etiology chronic heart failure patients at the insulin resistant stage? Health care of Kyrgyzstan 2022,No. 1, pp. 21-32. https://doi.org/10.51350/zdravkg202231320
Цитата үчүн

Курманбекова Б.Т., Рустамбекова А.Р., Норузбаева А.М. Метформинди инсулинге каршылыктын стадиясында ишемиялык этиологиядагы өнөкөт жүрөк жетишсиздиги менен ооруган бейтаптарга дайындоо жагымдуубу? Кыргызстандын саламаттык сактоо 2022, № 1, б. 21-32.
https://doi.org/10.51350/zdravkg202231321
Авторы Курманбекова Б.Т., Рустамбекова А.Р., Норузбаева А.М.
Ссылка doi.org https://doi.org/10.51350/zdravkg202231320
Страницы 21-32
Ключевые слова хроническая сердечная недостаточность, инсулинорезистентность, метформин, клиническое течение
Русский
Об авторах

Курманбекова Бермет Темирбековна, младший научный сотрудник отделения хронической сердечной недостаточности, Национальный центр кардиологии и терапии имени академика М.Миррахимова, Бишкек, Кыргызская Республика;
Норузбаева Айгуль Мукашевна, доктор медицинский наук, профессор, заведующая отделением хронической сердечной недостаточности, Национальный центр кардиологии и терапии имени академика М.Миррахимова, Бишкек, Кыргызская Республика;
Рустамбекова Акмарал Рустамбековна, младший научный сотрудник отделения хронической сердечной недостаточности, Национальный центр кардиологии и терапии имени академика М. Миррахимова, Бишкек, Кыргызская Республика.
Полный текст

PDF (RUS)
Список литературы

1. Rosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev 2017; 3(1):52-55.doi:10.15420/cfr.2016:20:2
2. Joshua J.J, Justin B., Valery S.E et al. Renin-angiotensin-aldosterone system, glucose metabolism and incident of type 2 diabetes mellitus: MESA. https://doi.org/10.1161/JAHA.118.009890 Journal of the American Heart Association 2018;7:e009890
3. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 2012; 8(4):609-617. doi:10.1016/j.hfc.2012.06.005
4. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2):255–323.
5. Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic Effects of Metformin in the Failing Heart. Int J Mol Sci 2018;19(10):2869.
6. Wurm R, Resl M, Neuhold S, Prager R, Brath H, Francesconi C, et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Heart 2016; 102(19):1544–51.
7. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso, JS, Merkely B, et al. Risk related to pre–diabetes mellitus and diabetesmellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure 2016 Jan; 9(1):e002560.
8. Bilak JM, Gulsin GS, McCann GP. Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism January 2021. doi:10.1177/2042018820980235
9. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009 May 19; 119(19):2568-77.
10. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012 Apr 1; 61(4):944-53.
11. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. doi:10.3390/biom11121834
12. Larsen, A.H., Jessen, N., Nørrelund, H., Tolbod, L.P., Harms, H.J. et al (2020), A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail 22:1628-1637. https://doi.org/10.1002/ejhf.1656
13. Siyao He, Xin Qian, Yanyan Chen, Xiaoxia Shen et al "Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study", Journal of Diabetes Research vol. 2021, Article ID 5534387, 10 pages, 2021. https://doi.org/10.1155/2021/5534387
14. Han, Y., Xie, H., Liu, Y. et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery di seases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 18, 96 (2019). https://doi.org/10.1186/s12933-019-0900-7
15. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, et al The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 2012 Nov; 14(11):1303-10. doi: 10.1093/eurjhf/hfs106. Epub 2012 Jun 27. PMID: 22740509.
16. Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids 2014; 91:54-60. doi:10.1016/j.steroids.2014.08.016
17. Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr Metab Cardiovasc Dis 2017 Aug; 27(8):657-669. doi: 10.1016/j.numecd.2017.04.009. Epub 2017 May 10. PMID: 28709719.
18. Ohkuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017; 40(9):1203–9.
19. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119(1):70.e23-30.
20. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200–206
21. Top WMC, Lehert P, Schalkwijk CG, Stehouwer CDA, Kooy A. Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial. PLoS One 2021 Apr 8; 16(4):e0247939. doi:10.1371/journal.pone.0247939. PMID: 33830998; PMCID: PMC8031400.
22. Rosiak M, Postula M, Kaplon-Cieslicka A, Trzepla E et al Metformin treatment may be associated with decreased levels of NTproBNP in patients with type 2 diabetes. Adv Med Sci 2013; 58(2):362-8. doi: 10.2478/ams-2013-0009. PMID: 24327531.
23. Eltonsy S, Dufour Doiron M, Simard P, Jose C, Sénéchal M et al Effects of the combination of metformin and exercise on glycated hemoglobin, functional capacity, lipid profile, quality of life, and body weight. J Int Med Res 2019 Mar; 47(3):1131-1145. doi:10.1177/0300060518817164. Epub 2019 Jan 7. PMID: 30614342; PMCID: PMC6421378.
24. Banerjee S,Panas R. Diabetes and cardiorenal syndrome:Understanding the “Triple Threat”.Hellenic J Cardiol 2017; 58(5):342–7.

25. Ekundayo OJ, Muchimba M, Aban IB, Ritchie C, Campbell RC, Ahmed A. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am J Cardiol 2009; 103(1):88–92.
26. Kishi T, Hirooka Y. Cardiac complications in hypertension and diabetes: role of sympathetic nervous activity. Curr Hypertension Rev 2013; 9(4):274–7.
27. Damman K, Hillege HL, van Veldhuisen DJ. Albuminuria in heart failure: a CHARMing new risk factor? Lancet 2009;374(9689):506–8.
28. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006;17(8):2106–11
29. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22(4):584–603.
30. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med 2017; 166(3):191-200. doi:10.7326/M16-1901
31. Wiggers H, Køber L, Gislason G, Schou M, Poulsen MK, Vraa S, Nielsen OW, et al The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J 2021 Jan; 231:137-146. doi:10.1016/j.ahj.2020.09.020. Epub 2020 Oct 9. PMID: 33039340; PMCID: PM C7544566.
32. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. Doi: 10.3390/biom11121834.
Для цитирования

Курманбекова Б.Т., Рустамбекова А.Р., Норузбаева А.М. Является ли благоприятным назначение метформина у пациентов с хронической сердечной недостаточностью ишемической этиологии на этапе инсулинорезистентности? Здравоохранение Кыргызстана 2022, № 1, с. 21-32.
https://doi.org/10.51350/zdravkg202231321
Английский
About authors

Kurmanbekova Bermet Temirbekovna, young researcher at chronic heart failure division, National center of cardiology and internal medicine named after academician M.Mirrakhimov, Bishkek, Kyrgyz Republic;

Rustambekova Akmaral Rustambekovna, Junior Researcher, Department of Chronic Heart Failure, National Center for Cardiology and Therapy named after Academician M. Mirrakhimov,Bishkek, Kyrgyz Republic;
Noruzbaeva Aigul Mukashevna, MD, professor, the head of chronic heart failure division, National center of cardiology and internal medicine named after academician M.Mirrakhimov, Bishkek, Kyrgyz Republic.
Full text

PDF (RUS)
References

1. Rosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev 2017; 3(1): 52-55. doi:10.15420/cfr.2016:20:2
2. Joshua J.J, Justin B., Valery S.E et al. Renin-angiotensin-aldosterone system, glucose metabolism and incident of type 2 diabetes mellitus: MESA. https://doi.org/10.1161/JAHA.118.009890 Journal of the American Heart Association 2018;7:e009890
3. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 2012; 8(4):609-617. doi:10.1016/j.hfc.2012.06.005
4. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2):255–323.
5. Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic Effects of Metformin in the Failing Heart. Int J Mol Sci  2018;19(10):2869.
6. Wurm R, Resl M, Neuhold S, Prager R, Brath H, Francesconi C, et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Heart 2016; 102(19):1544–51.
7. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso, JS, Merkely B, et al. Risk related to pre–diabetes mellitus and diabetesmellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure 2016 Jan; 9(1):e002560.
8. Bilak JM, Gulsin GS, McCann GP. Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism January 2021. doi:10.1177/2042018820980235
9. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009 May 19; 119(19):2568-77.
10. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012 Apr 1; 61(4):944-53.
11. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. doi:10.3390/biom11121834
12. Larsen, A.H., Jessen, N., Nørrelund, H., Tolbod, L.P., Harms, H.J. et al (2020), A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail 22:1628-1637. https://doi.org/10.1002/ejhf.1656
13. Siyao He, Xin Qian, Yanyan Chen, Xiaoxia Shen et al "Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study", Journal of Diabetes Research vol. 2021, Article ID 5534387, 10 pages, 2021. https://doi.org/10.1155/2021/5534387
14. Han, Y., Xie, H., Liu, Y. et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery di seases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 18, 96 (2019). https://doi.org/10.1186/s12933-019-0900-7
15. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, et al The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 2012 Nov; 14(11):1303-10. doi: 10.1093/eurjhf/hfs106. Epub 2012 Jun 27. PMID: 22740509.
16. Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids 2014; 91:54-60. doi:10.1016/j.steroids.2014.08.016
17. Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr Metab Cardiovasc Dis 2017 Aug; 27(8):657-669. doi: 10.1016/j.numecd.2017.04.009. Epub 2017 May 10. PMID: 28709719.
18. Ohkuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017; 40(9):1203–9.
19. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119(1):70.e23-30.
20. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200–206
21. Top WMC, Lehert P, Schalkwijk CG, Stehouwer CDA, Kooy A. Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial. PLoS One 2021 Apr 8; 16(4):e0247939. doi:10.1371/journal.pone.0247939. PMID: 33830998; PMCID: PMC8031400.
22. Rosiak M, Postula M, Kaplon-Cieslicka A, Trzepla E et al Metformin treatment may be associated with decreased levels of NTproBNP in patients with type 2 diabetes. Adv Med Sci 2013; 58(2):362-8. doi: 10.2478/ams-2013-0009. PMID: 24327531.
23. Eltonsy S, Dufour Doiron M, Simard P, Jose C, Sénéchal M et al Effects of the combination of metformin and exercise on glycated hemoglobin, functional capacity, lipid profile, quality of life, and body weight. J Int Med Res 2019 Mar; 47(3):1131-1145. doi:10.1177/0300060518817164. Epub 2019 Jan 7. PMID: 30614342; PMCID: PMC6421378.
24. Banerjee S,Panas R. Diabetes and cardiorenal syndrome:Understanding the “Triple Threat”.Hellenic J Cardiol 2017; 58(5):342–7.

25. Ekundayo OJ, Muchimba M, Aban IB, Ritchie C, Campbell RC, Ahmed A. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am J Cardiol 2009; 103(1):88–92.
26. Kishi T, Hirooka Y. Cardiac complications in hypertension and diabetes: role of sympathetic nervous activity. Curr Hypertension Rev 2013; 9(4):274–7.
27. Damman K, Hillege HL, van Veldhuisen DJ. Albuminuria in heart failure: a CHARMing new risk factor? Lancet 2009;374(9689):506–8.
28. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006;17(8):2106–11
29. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22(4):584–603.
30. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med 2017; 166(3):191-200. doi:10.7326/M16-1901
31. Wiggers H, Køber L, Gislason G, Schou M, Poulsen MK, Vraa S, Nielsen OW, et al The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J 2021 Jan; 231:137-146. doi:10.1016/j.ahj.2020.09.020. Epub 2020 Oct 9. PMID: 33039340; PMCID: PM C7544566.
32. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. Doi: 10.3390/biom11121834.
For citation

Kurmanbekova B.T., Rustambekova A.R., Noruzbaeva A.M. Is Metformin beneficial in ischemic etiology chronic heart failure patients at the insulin resistant stage? Health care of Kyrgyzstan 2022,No. 1, pp. 21-32. https://doi.org/10.51350/zdravkg202231320
Кыргызский
Авторлор жөнүндө

Курманбекова Бермет Темирбековна, өнөкөт жүрөк жетишсиздиги бөлүмүнүн кенже илимий кызматкери, Академик М.Миррахимов атындагы улуттук кардиология жана терапия борбору, Бишкек, Кыргыз Республикасы;

Норузбаева Айгуль Мукашевна, медицина илимдеринин доктору, өнөкөт жүрөк жетишсиздиги бөлүмүнүн башчысы, Академик М.Миррахимов атындагы улуттук кардиология жана терапия борбору, Бишкек, Кыргыз Республикасы;

Рустамбекова Акмарал Рустамбековна, өнөкөт жүрөк жетишсиздиги бөлүмүнүн кенже илимий кызматкери, Академик М.Миррахимов атындагы улуттук кардиология жана терапия борбору, Бишкек, Кыргыз Республикасы.
Толук текст

PDF (RUS)
Шилтемелер

1. Rosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev 2017; 3(1): 52-55.doi:10.15420/cfr.2016:20:2
2. Joshua J.J, Justin B., Valery S.E et al. Renin-angiotensin-aldosterone system, glucose metabolism and incident of type 2 diabetes mellitus: MESA. https://doi.org/10.1161/JAHA.118.009890 Journal of the American Heart Association 2018;7:e009890
3. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 2012; 8(4):609-617. doi:10.1016/j.hfc.2012.06.005
4. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2):255–323.
5. Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic Effects of Metformin in the Failing Heart. Int J Mol Sci 2018;19(10):2869.
6. Wurm R, Resl M, Neuhold S, Prager R, Brath H, Francesconi C, et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Heart 2016; 102(19):1544–51.
7. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso, JS, Merkely B, et al. Risk related to pre–diabetes mellitus and diabetesmellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure 2016 Jan; 9(1):e002560.
8. Bilak JM, Gulsin GS, McCann GP. Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism January 2021. doi:10.1177/2042018820980235
9. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009 May 19; 119(19):2568-77.
10. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012 Apr 1; 61(4):944-53.
11. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. doi:10.3390/biom11121834
12. Larsen, A.H., Jessen, N., Nørrelund, H., Tolbod, L.P., Harms, H.J. et al (2020), A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail 22:1628-1637. https://doi.org/10.1002/ejhf.1656
13. Siyao He, Xin Qian, Yanyan Chen, Xiaoxia Shen et al "Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study", Journal of Diabetes Research vol. 2021, Article ID 5534387, 10 pages, 2021. https://doi.org/10.1155/2021/5534387
14. Han, Y., Xie, H., Liu, Y. et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery di seases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 18, 96 (2019). https://doi.org/10.1186/s12933-019-0900-7
15. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, et al The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 2012 Nov; 14(11):1303-10. doi: 10.1093/eurjhf/hfs106. Epub 2012 Jun 27. PMID: 22740509.
16. Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids 2014; 91:54-60. doi:10.1016/j.steroids.2014.08.016
17. Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr Metab Cardiovasc Dis 2017 Aug; 27(8):657-669. doi: 10.1016/j.numecd.2017.04.009. Epub 2017 May 10. PMID: 28709719.
18. Ohkuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017; 40(9):1203–9.
19. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119(1):70.e23-30.
20. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200–206
21. Top WMC, Lehert P, Schalkwijk CG, Stehouwer CDA, Kooy A. Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial. PLoS One 2021 Apr 8; 16(4):e0247939. doi:10.1371/journal.pone.0247939. PMID: 33830998; PMCID: PMC8031400.
22. Rosiak M, Postula M, Kaplon-Cieslicka A, Trzepla E et al Metformin treatment may be associated with decreased levels of NTproBNP in patients with type 2 diabetes. Adv Med Sci 2013; 58(2):362-8. doi: 10.2478/ams-2013-0009. PMID: 24327531.
23. Eltonsy S, Dufour Doiron M, Simard P, Jose C, Sénéchal M et al Effects of the combination of metformin and exercise on glycated hemoglobin, functional capacity, lipid profile, quality of life, and body weight. J Int Med Res 2019 Mar; 47(3):1131-1145. doi:10.1177/0300060518817164. Epub 2019 Jan 7. PMID: 30614342; PMCID: PMC6421378.
24. Banerjee S,Panas R. Diabetes and cardiorenal syndrome:Understanding the “Triple Threat”.Hellenic J Cardiol 2017; 58(5):342–7.

25. Ekundayo OJ, Muchimba M, Aban IB, Ritchie C, Campbell RC, Ahmed A. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am J Cardiol 2009; 103(1):88–92.
26. Kishi T, Hirooka Y. Cardiac complications in hypertension and diabetes: role of sympathetic nervous activity. Curr Hypertension Rev 2013; 9(4):274–7.
27. Damman K, Hillege HL, van Veldhuisen DJ. Albuminuria in heart failure: a CHARMing new risk factor? Lancet 2009;374(9689):506–8.
28. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006;17(8):2106–11
29. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22(4):584–603.
30. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med 2017; 166(3):191-200. doi:10.7326/M16-1901
31. Wiggers H, Køber L, Gislason G, Schou M, Poulsen MK, Vraa S, Nielsen OW, et al The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J 2021 Jan; 231:137-146. doi:10.1016/j.ahj.2020.09.020. Epub 2020 Oct 9. PMID: 33039340; PMCID: PM C7544566.
32. Salvatore T, Galiero R, Caturano A, et al. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021; 11(12):1834. Published 2021 Dec 4. Doi: 10.3390/biom11121834.
Цитата үчүн

Курманбекова Б.Т., Рустамбекова А.Р., Норузбаева А.М. Метформинди инсулинге каршылыктын стадиясында ишемиялык этиологиядагы өнөкөт жүрөк жетишсиздиги менен ооруган бейтаптарга дайындоо жагымдуубу? Кыргызстандын саламаттык сактоо 2022, № 1, б. 21-32.
https://doi.org/10.51350/zdravkg202231321
Просмотров: 6254
Copyright MAXXmarketing GmbH
JoomShopping Download & Support